AKT1 and systemic sclerosis: Similarly, in localized scleroderma and systemic sclerosis, JAK inhibitors have shown beneficial clinical responses, including improvements in skin fibrosis, inflammation, and functional outcomes, with additional evidence of antifibrotic effects through modulation of the PI3K/Akt/mTOR signaling pathway [73,74].